Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: GlobeNewswire
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial with imdusiran in first half of 2024 Claim Construction for Moderna LNP litigation occurred on February 8, 2024; trial date set for April 21, 2025 Strong financial position with cash and investments of $132M; cash runway into Q1 2026 Conference Call and Webcast Today at 8:45 am ET WARMINSTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today reports fourth quarter and year end 2023 financial results and provides a corporate update. “I anticipate that 2024 will be a productive year for Arbutus as we continue to advance the deve
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswire
- Arbutus Biopharma Co. (NASDAQ: ABUS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock.MarketBeat
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaGlobeNewswire
- Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
ABUS
Earnings
- 11/7/23 - In-Line
ABUS
Sec Filings
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form DEF
- 4/4/24 - Form 8-K
- ABUS's page on the SEC website